Anzeige
Mehr »
Login
Dienstag, 19.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Solarbetriebenes Krypto-Mining: Die Strategie, die diese Aktie um 75?% steigen ließ!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
337 Leser
Artikel bewerten:
(1)

Fishawack Health unveils an unrivaled global market access and HEOR offering with the acquisition of PRMA Consulting

Finanznachrichten News

Fishawack Health bolsters its strong strategic offering by acquiring PRMA Consulting - a global market access and HEOR consulting leader with significant expertise in US, EU, and Asia-Pacific markets

LONDON, March 24, 2021 /PRNewswire/ -- Leading life science commercialization partner Fishawack Health has acquired PRMA Consulting, a premier global market access and health economics outcomes research (HEOR) consultancy with offices across Europe, Asia, and the US.

(From left to right) Jayne Sykes, Partner; David Sykes, Founding Partner; and Sotiria Papanicolaou, Partner, lead the PRMA Consulting team

The acquisition bolsters Fishawack Health's strong strategic offering, adding deep expertise in Asia-Pacific and European markets to complement the company's existing market access offering in North America. Fishawack Health now offers one of the industry's leading market access and HEOR capabilities, spanning the globe.

"We're delighted to welcome PRMA Consulting to our group - our third acquisition of 2021," Oliver Dennis, Fishawack Health Co-founder, and CEO, said. "PRMA Consulting brings extensive global market access, HEOR, and disease area expertise, making them an important addition to our Consulting business unit. By acquiring best-in-class organizations like PRMA Consulting, we are continuously developing agile, integrated, and tailored solutions that ensure we're one step ahead of our client's complex and evolving needs across the product lifecycle - from laboratory assets to launch and beyond."

For more than a decade, PRMA Consulting has shaped the future of market access with an industry-leading strategic offering and award-winning, cloud-based digital applications that unlock and optimize product value - the PRMA Healthcheck, PRMA Navigator, PRMA Tracker, and PRMA Access Accelerator. Fishawack Health intends to make these solutions available to all existing clients.

Fishawack Health Head of Consulting, Fred Bassett, said: "Our goal at Fishawack Health is to give clients access to highly-experienced experts who provide strategic direction, helping to make decisions that matter across the development and commercialization of portfolios, products, and services. The PRMA Consulting team shares our passion for solving the most complex and challenging healthcare problems in fast-evolving markets. We're delighted to add a team of market access and health economics strategists with deep specialism in HEOR, healthcare technology assessments, pricing, and reimbursement processes."

David Sykes, Founding Partner at PRMA Consulting, explained: "We are excited about the opportunity of joining Fishawack Health and building out the leading global value, evidence, and access group. We were drawn by our shared culture and values and the ability to tap into existing complementary Fishawack Health resources, which will help us provide our clients with an even better experience.

"As the pace of clinical development accelerates and the responsibilities between medical, commercial, access, and HEOR merge, we see a huge opportunity to develop market-leading integrated and cross-functional service offerings for our clients.

"We would like to thank our clients for helping us achieve this important milestone. I would also like to recognize and thank the wonderful team at PRMA Consulting who have helped us to be so successful. As our journey progresses, we remain focused on partnering with clients to help them enable faster patient access to therapies that improve health outcomes."

About Fishawack Health
Visit:?www.fishawack.com?

About PRMA Consulting
Visit: www.prmaconsulting.com

Advisers involved in this transaction included:
KPMG Manchester acted on behalf of Fishawack Health for financial and tax due diligence; Craig Scott and Elan Iorwerth, Hill Dickinson (Liverpool), together with Jamie Mercer and Lyle LeBlang, Sheppard Mullin (San Diego), and Allen & Overy (London) provided legal support; and EY provided tax advice. PricewaterhouseCoopers acted on behalf of PRMA Consulting for corporate finance. Charles Russell Speechlys LLP provided legal support and due diligence, and Marcussen Consulting LLP provided Tax advice and due diligence.

Photo - https://mma.prnewswire.com/media/1471132/Fishawack_Health_Picture1.jpg

© 2021 PR Newswire
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.